1. Pink Sheet
  2. >>Drug Safety

EU: Doctors Told Not To Use Defitelio As A Prophylactic For VOD

 
• By Vibha Sharma

While Defitelio is not authorized in the EU for the prevention of veno-occlusive disease (VOD), the European Medicines Agency wants health professionals to be informed about the results of a recent study in which the drug showed no benefit in this indication.

liver
Defitelio is approved for treating hepatic VOD in patients undergoing stem cell transplant • Source: Shutterstock

Gentium SRL, a Jazz Pharmaceuticals company, will be writing to health care professionals in the EU advising them that its orphan drug Defitelio (defibrotide) should not be used to prevent liver veno-occlusive disease (VOD) in patients undergoing blood stem cell transplantation.

The company’s proposed direct health care professional communication (DHPC) to this effect was reviewed by the European Medicines Agency’s pharmacovigilance...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Drug Safety

More from Pink Sheet

National Priority Voucher Gives US FDA Commissioner Tool For Radical Regulatory Surgery

 
• By Bridget Silverman

US FDA Commissioner Martin Makary will establish "national priorities" used to select sponsors for the pilot of “tumor board-style” drug reviews that would start before Phase III is completed.

US FDA’s CoGenT Pilot At Risk? Project Orbis Success May Not Save Cell/Gene Therapy Initiative

 
• By Bridget Silverman

Despite following the path of the popular Project Orbis, the cell and gene therapy international collaborative review pilot is being reconsidered by the FDA's new management.

HTA Expert Warns Of Escalating Measures If Pharma Fails To Tame Prices

 
• By Francesca Bruce

Too many “uninformative” drug trials fail to justify the excessively high prices of many medicines, while there is too much evidentiary uncertainty in European pricing and reimbursement systems, warned Anja Schiel from Norway’s NOMA.